The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development.

The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development.
复制标题

DOI:
10.1002/cpt.951
复制
发表时间:
2018-03
影响因子:
6.7
通讯作者:
Roden DM
Roden DM
中科院分区:
医学2区
文献类型:
--
作者:
Denny JC;Van Driest SL;Wei WQ;Roden DM

文献摘要

参考文献

被引文献

相似文献

药物开发仍然是昂贵和缓慢的,药物由于缺乏疗效或毒性而失败。药物基因组学发现的前景包括根据个体的基因组成定制治疗方法,合理的药物开发和重新利用药物。与电子健康记录(EHR)数据相关的大型研究队列的快速增长,推动了预测药物作用的新遗传变异的发现,支持孟德尔随机化实验以显示药物疗效,并为现有药物提供了新的适应症。新的生物医学信息学和机器学习方法提高了解释临床信息的能力,从而能够识别复杂的表型和患者亚群。我们回顾了最近的历史,使用“大数据”从EHR为基础的队列和生物银行支持这些活动。未来使用EHR数据、其他信息源和新方法的研究将为更快地推进精准医学奠定基础。
Drug development continues to be costly and slow, with medications failing due to lack of efficacy or presence of toxicity. The promise of pharmacogenomic discovery includes tailoring therapeutics based on an individual's genetic makeup, rational drug development, and repurposing medications. Rapid growth of large research cohorts, linked to electronic health record (EHR) data, fuels discovery of new genetic variants predicting drug action, supports Mendelian randomization experiments to show drug efficacy, and suggests new indications for existing medications. New biomedical informatics and machine learning approaches advance the ability to interpret clinical information, enabling identification of complex phenotypes and subpopulations of patients. We review the recent history of use of “big data” from EHR-based cohorts and biobanks supporting these activities. Future studies using EHR data, other information sources, and new methods will promote a foundation for discovery to more rapidly advance precision medicine.
DOI: 10.1038/nrd.2016.234
发表时间: 2017-01
期刊: Nature reviews. Drug discovery
影响因子: --
作者:
Giacomini KM;Yee SW;Mushiroda T;Weinshilboum RM;Ratain MJ;Kubo M
通讯作者: Kubo M
DOI: 10.1097/fpc.0b013e32834e1641
发表时间: 2012-01
影响因子: 2.6
作者:
Birdwell KA;Grady B;Choi L;Xu H;Bian A;Denny JC;Jiang M;Vranic G;Basford M;Cowan JD;Richardson DM;Robinson MP;Ikizler TA;Ritchie MD;Stein CM;Haas DW
通讯作者: Haas DW
DOI: 10.1038/nbt.2749
发表时间: 2013-12
影响因子: 46.9
作者:
通讯作者: --
DOI: 10.1371/journal.pone.0122271
发表时间: 2015
期刊: PloS one
影响因子: 3.7
作者:
Diogo D;Bastarache L;Liao KP;Graham RR;Fulton RS;Greenberg JD;Eyre S;Bowes J;Cui J;Lee A;Pappas DA;Kremer JM;Barton A;Coenen MJ;Franke B;Kiemeney LA;Mariette X;Richard-Miceli C;Canhão H;Fonseca JE;de Vries N;Tak PP;Crusius JB;Nurmohamed MT;Kurreeman F;Mikuls TR;Okada Y;Stahl EA;Larson DE;Deluca TL;O'Laughlin M;Fronick CC;Fulton LL;Kosoy R;Ransom M;Bhangale TR;Ortmann W;Cagan A;Gainer V;Karlson EW;Kohane I;Murphy SN;Martin J;Zhernakova A;Klareskog L;Padyukov L;Worthington J;Mardis ER;Seldin MF;Gregersen PK;Behrens T;Raychaudhuri S;Denny JC;Plenge RM
通讯作者: Plenge RM
DOI: 10.2337/dbi16-0069
发表时间: 2017-07-01
期刊: DIABETES
影响因子: 7.7
作者:
Florez, Jose C.
通讯作者: Florez, Jose C.